Skip to main content
PMC home page
AAPS PharmSciTech logoLink to AAPS PharmSciTech
. 2007 Oct 19;8(4):34–42. doi: 10.1208/pt0804085

Use of cyclodextrins as a cosmetic delivery system for fragrance materials: Linalool and benzyl acetate

Ulya Numanoğlu 1, Tangül Şen 1, Nilüfer Tarimci 1,✉, Murat Kartal 2, Otilia M Y Koo 3, Hayat Önyüksel 3
PMCID: PMC2750671  PMID: 18181546

Abstract

The aim of this study was to increase the stability and water solubility of fragrance materials, to provide controlled release of these compounds, and to convert these substances from liquid to powder form by preparing their inclusion complexes with cyclodextrins (CDs). For this purpose, linalool and benzyl acetate were chosen as the fragrance materials. The use of β-cyclodextrin (βCD) and 2-hydroxypropyl-β-cyclodextrin (2-HPβCD) for increasing the solubility of these 2 fragrance materials was studied. Linalool and benzyl acetate gave a B-type diagram with βCD, whereas they gave an AL-type diagram with 2-HPβCD. Therefore, complexes of fragrance materials with 2-HPβCD at 1:1 and 1:2 molar ratios (guest:host) were prepared. The formation of inclusion complexes was confirmed using proton nuclear magnetic resonance (1H-NMR) spectroscopy and circular dichroism spectroscopy. The results of the solubility studies showed that preparing the inclusion complex with 2-HPβCD at a 1:1 molar ratio increased the solubility of linalool 5.9-fold and that of benzyl acetate 4.2-fold, whereas the complexes at a 1:2 molar ratio increased the solubility 6.4- and 4.5-fold for linalool and benzyl acetate, respectively. The stability and in vitro release studies were performed on the gel formulations prepared using uncomplexed fragrance materials or inclusion complexes of fragrance materials at a 1:1 molar ratio. It was observed that the volatility of both fragrance materials was decreased by preparing the inclusion complexes with 2-HPβCD. Also, in vitro release data indicated that controlled release of fragrances could be possible if inclusion complexes were prepared.

Keywords: Cyclodextrin, benzyl acetate, linalool, solubility, stability, controlled release, inclusion complex

Full Text

The Full Text of this article is available as a PDF (310.2 KB).

References

  • 1.Healy LL. Gelled emollient systems for controlled fragrance release and enhanced product performance. Cosmet Toilet. 2002;117:47–54. [Google Scholar]
  • 2.Matsuda H, Ito K, Fujiwara Y, et al. Complexation of various fragrance materials with 2-hydroxypropyl-β-cyclodextrin. Chem Pharm Bull (Tokyo) 1991;39:827–830. [Google Scholar]
  • 3.Tanaka M, Matsuda H, Sumiyoshi H, et al. 2-Hydroxypropylated cyclodextrins as a sustained release carrier for fragrance materials. Chem Pharm Bull (Tokyo) 1996;44:416–420. [Google Scholar]
  • 4.Amann M, Dressnandt G. Solving problems with cyclodextrins in cosmetics. Cosmet Toilet. 1993;108:90–95. [Google Scholar]
  • 5.Loftsson T. Cyclodextrins in skin delivery. Cosmet Toilet. 2000;115:59–66. [Google Scholar]
  • 6.Del Valle EMM. Cyclodextrins and their uses: a review. Process Biochem. 2004;39:1033–1046. doi: 10.1016/S0032-9592(03)00258-9. [DOI] [Google Scholar]
  • 7.Motwani M, Zatz JL. Applications of cyclodextrins in skin products. Cosmet Toilet. 1997;112:39–47. [Google Scholar]
  • 8.Loftsson T, Másson M. Cyclodextrins in topical drug formulations: theory and practice. Int J Pharm. 2001;225:15–30. doi: 10.1016/S0378-5173(01)00761-X. [DOI] [PubMed] [Google Scholar]
  • 9.Másson M, Loftsson T, Másson G, Stefánsson E. Cyclodextrins as permeation enhancers: some theoretical evaluations and in vitro testing. J Control Release. 1999;59:107–118. doi: 10.1016/S0168-3659(98)00182-5. [DOI] [PubMed] [Google Scholar]
  • 10.Loftsson T, Ólafsdóttir BJ, Bodor N. The effects of cyclodextrins on transdermal delivery of drugs. Eur J Pharm Biopharm. 1991;37:30–33. [Google Scholar]
  • 11.Rogers K. Controlled release technology and delivery systems. Cosmet Toilet. 1999;114:53–60. [Google Scholar]
  • 12.Buschmann HJ, Schollmeyer E. Applications of cyclodextrins in cosmetic products: a review. J Cosmet Sci. 2002;53:185–191. [PubMed] [Google Scholar]
  • 13.Duchene D, Wouessıdjewe D. Physicochemical characteristics and pharmaceutical uses of cyclodextrin derivatives, Part I. Pharm Technol. 1990;14:26–34. [Google Scholar]
  • 14.Çelebi N, Kışlal Ö, Tarımcı N. The effect of β-cyclodextrin and penetration additives on the release of naproxen from ointment bases. Pharmazie. 1993;48:914–917. [Google Scholar]
  • 15.Anadolu RY, Sen T, Tarımcı N, Birol A, Erdem C. Improved efficacy and tolerability of retinoic acid in acne vulgaris: a new topical formulation with cyclodextrin complex. J Eur Acad Dermatol Venereol. 2004;18:416–421. doi: 10.1111/j.1468-3083.2004.00929.x. [DOI] [PubMed] [Google Scholar]
  • 16.Matsuda H, Ito K, Taki A, Uejima O, inventors. Shiseido Company Ltd., assignee. Cosmetic composition containing inclusion product with hydroxyalkylated cyclodextrin. US patent 5 447 920. September 5, 1995.
  • 17.Higuchi T, Connors KA. Phase-solubility techniques. Adv Anal Chem Instrum. 1965;4:117–210. [Google Scholar]
  • 18.Ajısaka N, Hara K, Mikuni K, Hara K, Hashimoto H. Effects of branched cyclodextrins on the solubility and stability of terpenes. Biosci Biotechnol Biochem. 2000;64:731–734. doi: 10.1271/bbb.64.731. [DOI] [PubMed] [Google Scholar]
  • 19.Lu CS, Hu CJ, Yu Y, Meng QJ. The inclusion compounds of β-cyclodextrin with 4-substituted benzoic acid and benzaldehyde drugs studied by proton nuclear magnetic resonance spectroscopy. Chem Pharm Bull (Tokyo) 2000;48:56–59. doi: 10.1248/cpb.48.56. [DOI] [PubMed] [Google Scholar]
  • 20.Choi HS, Knevel AM, Chang C. Molecular complexation: β-cyclodextrin and benzaldehyde inclusion complex. Pharm Res. 1992;9:690–693. doi: 10.1023/A:1015870631120. [DOI] [PubMed] [Google Scholar]
  • 21.Anguıano-Igea S, Otero-Espınar FJ, Vıla-Jato JL, Blanco-Mendez J. Interaction of clofibrate with cyclodextrin in solution: phase solubility1H NMR and molecular modelling studies. Eur J Pharm Sci. 1997;5:215–221. doi: 10.1016/S0928-0987(97)00277-7. [DOI] [Google Scholar]
  • 22.Frank SG. Inclusion compounds. J Pharm Sci. 1975;64:1585–1604. doi: 10.1002/jps.2600641003. [DOI] [PubMed] [Google Scholar]
  • 23.Szejtli J. Cyclodextrin Technology. Dordrecht, The Netherlands: Kluwer Academic Publishers; 1988. [Google Scholar]
  • 24.Bekers O, Uıjtendaal EV, Beıjnen JH, Bult A, Underberg WJM. Cyclodextrins in the pharmaceutical field. Drug Dev Ind Pharm. 1991;17:1503–1549. doi: 10.3109/03639049109026630. [DOI] [Google Scholar]
  • 25.Duchene D, Wouessidjewe D, Poelman MC. Dermal uses of cyclodextrins and derivatives. In: Duchêne D, editor. New Trends in Cyclodextrins and Derivatives. Paris, France: Editions de Sante; 1991. pp. 302–302. [Google Scholar]
  • 26.Frömming KH, Szejtli J. Cyclodextrins in Pharmacy. Dordrecht, The Netherlands: Kluwer Academic Publishers; 1994. [Google Scholar]

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists

RESOURCES